Evidence map›Paper›PMID 30339463›Full record

ReviewAmerican journal of respiratory cell and molecular biology2019

MARCKS and Lung Disease.

Mary K Sheats, Qi Yin, Shijing Fang, Joungjoa Park, Anne L Crews, Indu Parikh, Brian Dickson, Kenneth B Adler

Abstract readReview
In one paragraph

Review in American journal of respiratory cell and molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  4. Article
  5. Role for the PIPJournal of cell communication and signaling · 2024
    Review
  6. Article
  7. MARCKS and PI(4,5)PMolecular biology of the cell · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Peptide Inhibitors of MARCKS Suppress Endotoxin Induced Uveitis in Rats.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mary K Sheats1 Department of Clinical Sciences and.
Qi Yin2 Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina; and.
Shijing Fang2 Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina; and.
Joungjoa Park2 Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina; and.
Anne L Crews2 Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina; and.
Indu Parikh3 BioMarck Pharmaceuticals, Durham, North Carolina.
Brian Dickson3 BioMarck Pharmaceuticals, Durham, North Carolina.
Kenneth B Adler2 Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina; and.
North Carolina State University · USBioMarck Pharmaceuticals (United States) · US

Funding

Preclinical Development of a Therapeutic Agent for COPDR44HL073591 · NHLBI · BIOMARCK PHARMACEUTICALS, LTD · PI PARIKH, INDU · 2004 to 2015
$7.3M
Mechanism of Oxidant-Induced Respiratory Mucin SecretionR37HL036982 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI ADLER, KENNETH BRUCE · 2004 to 2013
$4.0M
TARGETING THE MARCKS-FAMILY PROTEINS TO INHIBIT NEUTROPHIL MIGRATIONK01OD015136 · OD · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI SHEATS, MARY KATHERINE · 2012 to 2016
$628k
A novel therapeutic approach for Acute Lung Injury/ARDSR41HL124817 · NHLBI · BIOMARCK PHARMACEUTICALS, LTD · PI ADLER, KENNETH BRUCE · 2014 to 2014
$202k
NHLBI NIH HHS R37 HL036982NHLBI NIH HHS R41 HL124817NHLBI NIH HHS R44 HL073591NIH HHS K01 OD015136
6 · The paper itself

Abstract

MARCKS (myristoylated alanine-rich C kinase substrate) is a prominent PKC substrate expressed in all eukaryotic cells. It is known to bind to and cross-link actin filaments, to serve as a bridge between Ca

Indexed as

AnimalsHumansLung DiseasesMyristoylated Alanine-Rich C Kinase SubstrateMyristoylated Alanine-Rich C Kinase Substratecancerinflammationlung diseaseMARCKS

Identifiers

PMID30339463
PMCPMC6348718
OpenAlexW2897732128

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.